Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian
tube or primary peritoneal or witch it was decided to initiate a process comprising of
Bevacizumab (Avastin ®) in first-line therapy
Observational [Patient Registry]
Observational Model: Cohort, Time Perspective: Prospective
Safety according to CTCAE v4.0 criteria
To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.
Patient will be followed dureing 36 months
Yes
Dominique BERTON-RIGAUD, MD
Principal Investigator
ICO de l'Ouest, Site René Gauducheau - Saint-Herblain
France: The National Commission for Informatics and Liberties (CNIL in french)
ENCOURAGE (GINECO-OV123)
NCT01832415
April 2013
January 2018
Name | Location |
---|